Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal:

Journal of Clinical Oncology

Published:

2026-02-21

DOI:

10.1200/jco-25-01808

Affiliations:

24

Authors:

25

Go to article

Institutions	Authors	Share
Vall d'Hebron University Hospital (HUVH), ICS, Spain	2.000000	0.08
Institute of Biomedicine of Seville (IBiS), Spain	2.000000	0.08
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain	1.666667	0.07
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy	1.000000	0.04
Instituto de Investigación Marqués de Valdecilla (IDIVAL), HUMV, Spain	1.000000	0.04
University Hospital Alvaro Cunqueiro, Spain	1.000000	0.04
Consorci Hospital General Universitario de Valencia (CHGUV), Spain	1.000000	0.04
Sant'Andrea Hospital, Italy	1.000000	0.04
Hospital Universitario Ramón y Cajal, Spain	1.000000	0.04
Hospital Universitario de Burgos, Spain	1.000000	0.04
Hospital La Paz Institute for Health Research (IdiPAZ), Spain	1.000000	0.04
Hospital Universitario de Salamanca (HUS), USAL, Spain	1.000000	0.04
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	1.000000	0.04
IRCCS European Institute of Oncology (IEO), Italy	1.000000	0.04
Donostia University Hospital, Spain	1.000000	0.04
Gregorio Marañon University Hospital, Spain	1.000000	0.04
Asturias Central University Hospital (HUCA), Spain	1.000000	0.04
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain	1.000000	0.04
MD Anderson Cancer Center Madrid, Spain	1.000000	0.04
Bellvitge Biomedical Research Institute (IDIBELL), Spain	1.000000	0.04
Hospital Universitario 12 de Octubre, Spain	0.666667	0.03
Complutense University of Madrid (UCM), Spain	0.666667	0.03
Hospital Universitario Virgen de las Nieves (HUVN), Spain	0.500000	0.02
Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Spain	0.500000	0.02

Interested in Clinical Sciences?